Danish Semaglutide Users Achieve Significant Weight Loss and Concomitant Medication Reductions at 1 mg Dose
Background
The global burden of obesity and overweight continues to rise, necessitating effective long-term treatment strategies. GLP-1 receptor agonists like semaglutide have demonstrated significant efficacy in clinical trials for weight management, but real-world adherence to recommended dose titration schedules and treatment patterns often deviates. Understanding these real-world usage patterns is crucial for optimizing patient outcomes and informing clinical guidance, especially regarding the potential for achieving desired effects at lower doses than those typically recommended for maximum efficacy in trials. This study addresses the gap in understanding how Danish adults use semaglutide outside of controlled trial settings.
Study Design
A cross-sectional, questionnaire-based survey was conducted across 28 Danish community pharmacies between March and May 2025. Adult individuals redeeming a prescription for semaglutide for weight management (SEMA-WM) were invited to participate. The study aimed to characterize real-world treatment patterns, including current dose, duration of use, and self-reported effects. First-time users were also invited to a follow-up survey after 6 months. The primary endpoints included reported weight loss, current dosing patterns, and changes in concomitant medication use. Data was collected via a structured questionnaire, capturing user experiences and adherence.
Results
Of 1470 invited individuals, 767 (52%) completed the questionnaire. A significant portion, 45%, reported using 1 mg as their current dose, with only 8% expecting to reach 2.4 mg. Concerning adherence, 10% reported dosing SEMA-WM by 'counting clicks' on the injection pen, contrary to official guidelines. Users treated for 1-3 months reported a median weight loss of 6% (IQR 3-7), which progressively increased with treatment duration. Users treated for 3-6 months saw 12% (IQR 9-14), 6-12 months achieved 17% (IQR 12-21), and those treated for >1 year reported a median weight loss of 20% (IQR 15-26). Notably, weight loss by treatment duration was similar among 1 mg users. > Twenty-four percent of users reported reduced or discontinued concomitant medication use after initiating SEMA-WM, particularly for muscle/joint pain (30%) and antihypertensives (24%). This reduction was also similar among 1 mg users. Among 42 first-time users, 83% were still using SEMA-WM after 6 months, with 60% typically on 1 mg. Side effects were the most common reason for discontinuation (17% of users).
Key Findings
- 45% of semaglutide users for weight management were currently on a 1 mg dose.
- Median weight loss reached 20% (IQR 15-26) after >1 year of semaglutide use.
- Weight loss outcomes were similar for users on 1 mg across different treatment durations.
- 24% of users reduced or discontinued concomitant medications, especially for muscle/joint pain (30%) and antihypertensives (24%).
- Among first-time users, 83% continued semaglutide after 6 months, with 60% on 1 mg.
Why It Matters
This real-world data suggests that many individuals using semaglutide for weight management may achieve substantial weight loss and reduce other medications even at lower doses like 1 mg, challenging the conventional wisdom of titrating to the maximum approved dose. Individualized semaglutide dosing strategies could become a more prominent discussion point for clinicians and users, potentially leading to better tolerability, reduced side effects, and more cost-effective treatment. For biohackers and peptide users, this implies that a 'less is more' approach might be viable for sustained weight management with semaglutide, potentially extending supply or mitigating side effects often associated with higher doses. This study underscores the need for better guidance on personalized treatment trajectories, moving beyond a one-size-fits-all titration schedule to optimize patient outcomes and resource utilization.
semaglutide
weight-management
obesity
real-world-evidence
survey
glp-1-agonist